Gene therapies for cardiovascular conditions could aim to mimic drug effects, such as knocking out PCSK9 to address hyperlipidemia.

“if genetic therapies and treatments are going to be deployed against conditions especially like f you would really do it to more mimic the drug than you would to try to correct the defect and that makes a lot of sense in the case of FH because of the heterogeneity right there's no you know to have 5,000 different Gene therapies for the 5,000 different genes that can be altered in the result of of of hyperlipidemia is is a bad idea whereas if you can simply knock out pcsk9 as a gene you basically take care of everyone”